Most cited papers from OnCore Biopharma (United States)
What are the most cited papers from OnCore Biopharma (United States)?
The most cited paper from OnCore Biopharma (United States) is "Nucleotide Prodrugs for the Treatment of HCV Infection" (Michael J. Sofia, 2013), with 50 citations. Next come "Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?" (44) and "Nucleosides and Nucleotides for the Treatment of Viral Diseases" (4).
Showing 3 of 3 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Nucleotide Prodrugs for the Treatment of HCV Infection Michael J. Sofia · Advances in pharmacology | 2013 | 50 |
| 2 | Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Michael J. Sofia · Antiviral Research | May 2014 | 44 |
| 3 | Nucleosides and Nucleotides for the Treatment of Viral Diseases Michael J. Sofia · Annual reports in medicinal chemistry | 2014 | 4 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.